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Abstract
The echinodermmicrotubule–associated protein-like 4–anaplastic lymphoma kinase (EML4-ALK) fusion gene result-
ing from an inversion within chromosome 2p occurs in approximately 5% of non–small cell lung cancer and is mu-
tually exclusivewith Ras and EGFRmutations. In this study, we have used a potent and selective ALK small molecule
inhibitor, NPV-TAE684, to assess the oncogenic role of EML4-ALK in non–small cell lung cancer (NSCLC). We show
here that TAE684 inhibits proliferation and induces cell cycle arrest, apoptosis, and tumor regression in two NSCLC
models that harbor EML4-ALK fusions. TAE684 inhibits EML4-ALK activation and its downstream signaling including
ERK, AKT, and STAT3. We used microarray analysis to carry out targeted pathway studies of gene expression
changes in H2228 NSCLC xenograft model after TAE684 treatment and identified a gene signature of EML4-ALK
inhibition. The gene signature represents 1210 known human genes, and the top biologic processes represented
by these genes are cell cycle, DNA synthesis, cell proliferation, and cell death. We also compared the effect of
TAE684 with PF2341066, a c-Met and ALK small molecule inhibitor currently in clinical trial in cancers harboring
ALK fusions, and demonstrated that TAE684 is a much more potent inhibitor of EML4-ALK. Our data demonstrate
that EML4-ALK plays an important role in the pathogenesis of a subset of NSCLC and provides insight into themech-
anism of EML4-ALK inhibition by a small molecule inhibitor.
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Introduction
Anaplastic lymphoma kinase (ALK) is implicated in the oncogenesis of
both hematopoietic and nonhematopoietic malignancies, and there is
a strong rationale for ALK inhibition as a targeted therapy against
cancers harboring oncogenic alterations of ALK [1]. ALK was first
identified as a fusion protein containing the N-terminal portion of
nucleophosmin (NPM) and the intracellular domain of ALK, which
results from the t(2;5)(p23;q35) chromosomal rearrangement present
in 60% to 70% of anaplastic large cell lymphomas (ALCLs) [2]. The
oligomerization domain in NPM leads to dimerization and constitu-
tive activation of NPM-ALK, which has been shown to transform var-
ious hematopoietic cell types in vitro and support tumor formation
in vivo [3–6]. A causative role of NPM-ALK in pathogenesis of ALCL
has been established [7–9]. NPM-ALK mediates oncogenesis, at least
in part, through activation of PI3K/Akt, Jak/STAT, and Raf/MEK/
ERK signaling pathways, resulting in increased cell proliferation and
resistance to apoptosis [10,11].
Recently, by screening a retroviral complementary DNA expres-
sion library generated from a non–small cell lung cancer (NSCLC)
patient tumor sample, a novel ALK fusion protein EML4-ALK was
identified [12] as a result of a small inversion within the short arm of
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chromosome 2. EML4-ALK is present in 3% to 7% of NSCLC and
is mutually exclusive with K-Ras and EGFRmutations [12–16]. To date,
at least seven EML4-ALK variants have been identified, based on the
number of exons in EML4 fused to ALK [12–14,17,18]. All EML4-
ALK fusions contain a coiled-coil domain within EML4 that mediates
constitutive dimerization and activation of EML4-ALK. Overexpression
of EML4-ALK in mouse 3T3 fibroblasts resulted in the formation of
transformed foci in culture and subcutaneous tumors in nude mice
[12]. Furthermore, transgenic mice that express EML4-ALK specifically
in lung alveolar epithelial cells developed adenocarcinoma nodules in
both lungs within a few weeks after birth, and treatment of these mice
with an ALK small molecule inhibitor (SMI) resulted in rapid disappear-
ance of the tumors [19]. These data suggest that EML4-ALK plays a piv-
otal role in the pathogenesis of NSCLC.
In this study, we used a potent and selective ALK SMI TAE684
[9,20] and two human NSCLC models [13,14,20] that harbor
EML4-ALK fusion proteins to investigate further the oncogenic role
of ALK fusions in NSCLC. Our results demonstrated that TAE684
inhibits cell proliferation, induces cell cycle arrest and apoptosis, and
regresses established xenograft tumors of NSCLC. We show that
EML4-ALK shares similar downstream signaling pathways with
NPM-ALK, including Akt, ERK, and STAT3, which are inhibited
by TAE684 treatment. We identified a gene signature of EML4-ALK
inhibition by TAE684 in the NSCLC model that could be used as po-
tential pharmacodynamic (PD) biomarkers to monitor the efficacy of
treatment by ALK SMIs. In addition, we compared the efficacy of
PF2341066, a c-met and ALK SMI in clinical development [21–23],
with TAE684 in NSCLC models and demonstrated that PF2341066
is not as potent compared with TAE684 in inhibiting EML4-ALK
oncogenic functions in vitro and in vivo.
Materials and Methods
Antibodies
Antibodies against human ALK, phospho-ALK (Tyr1604), Akt,
phospho-Akt (Ser 473), ERK, phospho-ERK (Thr202/Tyr204),
STAT3, and phospho-STATA3 (Tyr705) were obtained from Cell Sig-
naling (Danvers, MA).
Cell Lines and Culture
Human NSCLC cell lines H2228 and H3122 were obtained from
ATCC (Manassas, VA) and National Cancer Institute (Bethesda,
MD), respectively. Cells were cultured in RPMI 1640medium supple-
mented with 10% fetal bovine serum. The cells have been tested for
EML4-ALK fusions by reverse transcription–polymerase chain reac-
tion regularly while maintained in culture.
Kinase Inhibitor
TAE684 and PF2341066 were synthesized following published
procedures [9,21]. The structures of the compounds were confirmed
by H nuclear magnetic resonance and the purity was determined by
high-performance liquid chromatography at a wavelength of 254 nm
as 100% pure.
Proliferation and Apoptosis Assays
Cells were seeded at 5000 cells per well in 96-well plates and treated
with TAE684 at various doses (dose range, 1-1000 nM) for 24 to
72 hours. Cell proliferation was measured using CellTiter-Glo Lumi-
nescent Cell Viability Assay, and apoptosis was measured using
Caspase3/7–Glo assay (Promega, Madison, WI) following the man-
ufacturer’s instructions.
Cell Cycle Analysis and Annexin V Staining
H2228 and H3122 cells were treated with 50 or 200 nM TAE684
for 24 hours and then synchronized [24] with hydroxyurea (HU).
Cells were arrested in HU for 20 hours and released, and the cell cycle
distribution was determined by flow cytometry. For cell cycle analysis,
cells were harvested, fixed in 70% ethanol at 4°C overnight, washed
in PBS, and treated with RNase A (0.1 mg/ml; Sigma, St Louis, MO)
and propidium iodide (50 μg/ml; Sigma) for 30 minutes at 37°C.
Samples were analyzed on FACScalibur Flow Cytometer (BD Bioscience,
San Jose, CA). Cell apoptosis was determined using the annexin V–PE
ApoptosisDetectionKit (BDBiosciences, San Jose, CA95131) according
to the manufacturer’s instruction. Cell cycle distribution and percent of
apoptotic cells were analyzed by FlowJo Data Analysis Software.
Xenograft Experiments
All studies were conducted in accordance with the Guidance for the
Care and Use of Laboratory Animals (National Institutes of Health,
Bethesda, MD) and approved by Institutional Animal Care and Used
Committee. A total of 5 × 106 cells were implanted subcutaneously
into the right flank of nude mice. When the tumor size reached
300 mm3 (H2228 and H3122) or 100 mm3 (A549), mice were ran-
domized into different treatment groups (n = 10 for each group).
TAE684 and PF2341066 were administered daily by oral gavage in
formulations as described previously [9,21]. Tumor volume was mea-
sured twice weekly for 15 to 25 days. Statistical analyses were per-
formed using two-way analysis of variance for comparison of tumor
growth in different treatment groups.
For PD studies, mice bearing established tumors (mean size,
300 mm3) were treated with TAE684 at 15 mg/kg (H2228) or
30 mg/kg (H3122) for 0, 24, 48, and 72 hours. At each time point,
tumors were excised, messenger RNA (mRNA) was extracted for
microarray, and cell lysates were prepared for Western blot analysis.
Tumor samples were fixed in formalin, and Ki-67 and cleaved caspase
3 (CC3) immunohistochemistry (IHC) was performed. For apoptosis
analysis, tumor cells were separated from associated leukocytes by sort-
ing out CD45-positive cells, stained with annexin V, and followed by
flow cytometry.
Microarray Analysis
Messenger RNA expression profiling of H2228 xenograft tumors
treated with TAE684 for 0, 24, 48, and 72 hours was carried out on
Affymetrix GeneChipHumanGenomeU133 Plus 2.0 Array as per the
manufacturer’s protocol. Expression summary values for all probe sets
were calculated using the RMA algorithm as implemented in the rma
package from Bioconductor [25]. Statistical analyses of differentially
expressed genes were performed using linear models and empirical
Bayes moderated statistics as implemented in the limma package from
Bioconductor. To obtain the biologic processes that are overrepresented
by the differentially expressed genes, hypergeometric tests for associ-
ation of Gene Ontology (GO) biologic process categories and genes
were performed using the GOstats and Category packages, and
P values for high-level generic GO slim terms were reported. The list
of genes involved in cell cycle and apoptosis pathways was compiled
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from related canonical pathway gene sets from the Molecular Signa-
tures Database (http://www.broadinstitute.org/gsea/msigdb/index.jsp).
Hierarchical clustering of the expression profile was performed using
the Pearson correlation as the similarity measure and complete linkage
as the agglomeration method. The list of potential biomarkers was gen-
erated using Ingenuity Pathways Analysis (Ingenuity Systems, http://
www.ingenuity.com).
Results
TAE684 Induces Apoptosis and Cell Cycle Arrest of H2228
NSCLC Cells
To evaluate the role of EML4-ALK in NSCLC, we first tested the
effect of TAE684, a selective ALK SMI [9,20] (Supplemental Data,
Figure W1) on NSCLC cell line H2228 that expresses EML4-ALK
variant 3, containing exons 1 to 6 of EML4 [13]. TAE684 reduced via-
bility of H2228 cells in a dose-dependent manner (Figure 1A), with an
IC50 (50% inhibition) of 15 nM. This decrease in cell viability is caused
in part by TAE684-induced apoptosis as demonstrated by the increased
activation of caspase 3/7 (Figure 1B) and annexinV staining (Figure 1C ).
Seventy-two hours after TAE684 treatment, annexin V–positive cells
increased from 21% to 38% (50 nM TAE684) and 43% (200 nM
TAE684; Figure 1C ). To test the impact of TAE684 on cell cycle pro-
gression, TAE684-treated H2228 cells were stained with propidium
iodide (PI) and analyzed for cell cycle distribution. InH2228 cells treated
with TAE684 for 24 hours, 96% cells were arrested in G1 phase
compared with 56% of cells in vehicle-treated control (Figure 1D).
Collectively, these results suggest that TAE684 inhibits the growth of
Figure 1. TAE684 inhibits cell proliferation, induces apoptosis and cell cycle arrest, and inactivates EML4-ALK signaling of H2228 cells.
(A) TAE684 reduces H2228 cell survival. Cells were treated with indicated concentrations of TAE684 and cell viability was measured by
CellTiterGlo 72 hours after treatment. (B, C) TAE684 induces apoptosis. Cells were treated with indicated concentrations of TAE684.
Caspase 3/7 activation wasmeasured by Cap3/7Glo 48 hours after treatment (B). Cells were treated with 50 or 200 nM TAE684; apoptosis
was measured at indicated time by annexin V stain 72 hours after treatment (C). (D) TAE684 induces G1 arrest. Cells were treated with
200 nM TAE684 for 24 hours, arrested at G1/S transition with HU, and released into the S phase. Cells were harvested at indicated time,
stained with PI, and analyzed for cell cycle distribution. Percentage of cells in G1 at various time points is shown. (E) TAE684 inhibits ALK
signaling. Cells were treated with 50 nM TAE684 for 6 hours, and Western blot analysis was performed to determine phosphorylation of
ALK, Akt, ERK, and STAT3.
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H2228 NSCLC cells by both induction of apoptosis and inhibition of
cell cycle progression, although TAE684-induced G1 arrest seems to be
the major mechanism that reduces H2228 growth.
In addition, TAE684 inhibited ALK activation and downstream signal-
ing. As shown in Figure 1E , 50 nMTAE684 inhibited phosphorylation
of ALK, Akt, STAT3, and ERK. These results suggest that EML4-ALK
activates ERK, PI3K/Akt, and STAT signaling in H2228 cells, similar
to NPM-ALK in ALCL cells.
TAE684 Induces Regression of Established H2228
Xenograft Tumors
Previous study has shown that TAE684 induces regression of estab-
lished lymphomas expressing NPM-ALK fusions [9]; we reasoned that
if EML4-ALK is the oncogenic driver in NSCLC, TAE684 should
have a similar effect on these tumors. To test this hypothesis, we estab-
lished the H2228 xenograft model. When the tumor size reached an
average of 300mm3,mice were randomized into control and three treat-
ment groups, and TAE684was administered by oral gavage at 5, 10, and
30 mg/kg per day. After 7 days of treatment, tumors in the TAE684
treatment group at all dose levels showed almost complete regression,
whereas tumors in the control group continues to grow (Figure 2A).
TAE684 had no effect on xenograft tumor growth of A549, an NSCLC
cell line that does not express ALK fusions, but contains K-Rasmutation
and expresses wild-type EGFR [26] (Figure 2A) and it did not affect the
body weight of treated mice (not shown). These results suggest that
TAE684 specifically inhibits EML4-ALK in H2228 tumors.
To understand the mechanisms involved in TAE684 inhibition of
H2228 tumor growth, we performed a pharmacodynamic study. Mice
bearing established H2228 xenograft tumors were treated with either
TAE684 (15mg/kg) or vehicle for 3 days. Immunoblot analysis of pro-
tein extracted from tumor revealed a reduction in the phosphorylation
levels of ALK downstream targets Akt, ERK, and STAT3, 24 hours after
dosing (Figure 2B). There was a time-dependent decrease in Ki-67–
positive cells with only 10% positive cells at 72 hours after dosing
Figure 2. TAE684 induces regression of established H2228 xenograft tumors. (A) TAE684 inhibits H2228 but not A549 xenograft tumor
growth. A total of 5 × 106 H2228 or A549 cells were implanted subcutaneously (sc) into nude mice. When the average tumor size reached
300mm3 (H2228) or 100mm3 (A549), mice were randomized into different treatment groups. TAE684was administered per os daily at the
indicated doses or vehicle (10%1-methyl-2-pyrrolidinone/90%PEG30).n=10 for each group.P=7.6×10−32 (control vs TAE684 5mg/kg),
P= 8 × 10−11 (TAE684 5 vs 15 mg/kg). (B) TAE684 inhibits EML4-ALK signaling in H2228 xenograft tumors. Established H2228 xenograft
tumors were treated with 15 mg/kg TAE684, cell lysates were prepared at the indicated time, andWestern blot analysis was performed to
measure phosphorylated Akt, ERK, and STAT3. (C, D) TAE684 inhibits proliferation and induces apoptosis of H2228 tumor cells. Estab-
lished H2228 xenogaft tumors were treated with 15 mg/kg TAE684, and Ki-67 IHC was performed at the indicated time to measure cell
proliferation. For apoptosis analysis, tumors were collected at the indicated time after dosing, and tumor cells were stained with annexin
V (n = 3 for each time point).
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(Figure 2C), suggesting that TAE684 strongly inhibits tumor cell prolif-
eration. TAE684 also induces tumor cell apoptosis as determined by an-
nexin V stain, with 40% of tumor cells undergoing apoptosis 72 hours
after dosing (Figure 2D). These results suggest that TAE684 inhibits
NSCLC tumor growth by inhibition of EML4-ALK signaling, which in
turn leads to decreased proliferation and increased apoptosis of tumor cells.
Effect of TAE684 on H3122 NSCLC Cells In Vitro
and In Vivo
To further assess the oncogenic role of EML4-ALK in NSCLC, we
tested the effect of TAE684 on another NSCLCmodel H3122, which
harbors EML4-ALK variant 1 containing exons 1 to 13 of EML4 [14].
TAE684 reduces H3122 cell viability in a dose-dependentmanner, with
an IC50 of 47 nM (Figure 3A), which is higher than the 15-nM IC50
(Figure 1A) observed in H2228 cell. The reduced cell viability by
TAE684 is likely due to the rapid induction of apoptosis; 50% of cells
were stained annexin V–positive 48 hours after TAE684 treatment
(Figure 3B). TAE684 does not seem to affect cell cycle progression in
this cell line (Figure 3C), suggesting that induction of apoptosis plays a
more important role in TAE684 inhibition of H3122 cell growth.
To test the effect of TAE684 on tumor growth in vivo, established
H3122 xenograft tumors were treated with TAE684 at 5 and 30mg/kg
per day. Figure 3D shows that, at 30 mg/kg, TAE684 induces tumor
regression, whereas at 5 mg/kg, it causes tumor growth stasis. These
Figure 3. Effect of TAE684 on H3122 NSCLC cells in vitro and in vivo. (A) TAE684 reduces H3122 viability. Cells were treated with
indicated concentrations of TAE684. Cell viability was measured by CellTiterGlo 72 hours after treatment. (B) TAE684 induces apoptosis.
Cells were treated with 200 nM TAE684, and apoptosis was measured at the indicated time after dosing by annexin V stain. (C) TAE684
does not affect cell cycle progression. Cells were treated with 200 nM TAE684 for 24 hours, arrested at G1/S transition with HU, and
released into the S phase. Cells were harvested at indicated time, stained with PI, and analyzed for cell cycle distribution. Percentage of
cells in G1 at various time points is shown. (D) TAE684 inhibits established H3122 xenograft tumor growth. A total of 5 × 10
6 cells were
implanted sc into nude mice. When the average tumor size reached 300 mm3, mice were randomized into different treatment groups.
TAE684 was administered per os daily at the indicated doses or vehicle (10% 1-methyl-2-pyrrolidinone/90% PEG30). n = 10 for each
treatment group. P = 10−7 (control vs TAE684 5 mg/kg), P = 5.6 × 10−30 (TAE684 5 vs 30 mg/kg). (E) TAE684 inhibits EML4-ALK sig-
naling in H3122 xenograft tumors. Established H3122 xenogaft tumors were treated with 30 mg/kg TAE684, cell lysates were prepared
at the indicated time, and Western blot analysis was performed to measure phosphorylated Akt, ERK, and STAT3. (F) TAE684 inhibits
proliferation of H3122 tumor cells. Established H3122 xenogaft tumors were treated with 30 mg/kg TAE684, and Ki-67 and CC3 IHC was
performed at the indicated time to measure cell proliferation and apoptosis, respectively (n = 5 for each time point).
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results are consistence with that of H2228 model; however, a higher
dose of TAE684 was required to achieve tumor regression given the
decreased potency in vitro.
We performed a pharmacodynamic study to examine the immediate
molecular effects of short-term TAE684 treatment on the established
H3122 tumors. Immunoblot analysis of protein extracts from xenograft
tumors revealed a reduction in phosphorylation levels of EML4-ALK
downstream signaling target STAT3 and Akt, but there was little change
in phosphorylated ERK (Figure 3E). Ki-67 IHC showed that treatment
of tumors with TAE684 resulted in a time-dependent reduction in
Ki-67–positive nuclei, from 50% in vehicle treated tumors to 7%
72 hours after administration of TAE684 (Figure 3F ). Furthermore,
TAE684 induces rapid apoptosis of tumor cells, as demonstrated by
cleaved caspase 3 (CC3) IHC (data not shown).
Taken together, these data showed that TAE684 is able to inactivate
EML4-ALK signaling, reduce cell survival in vitro, and inhibit xeno-
graft tumor growth in vivo. These results provide further evidence that
the EML4-ALK plays a pivotal role in the oncogenesis of NSCLC.
TAE684 Is a More Potent Inhibitor of EML4-ALK
than PF2341066
PF2341066, developed as c-Met SMI [21,22], also inhibits ALK
kinase activity, with IC50 of 4 and 24 nM in in vitro kinase assays
for c-met and ALK, respectively. It has been shown that PF2341066
inhibits ALCLs proliferation in vitro and xenograft tumor growth
in vivo [22]. A recent phase 1 clinical trial demonstrated that
PF2341066 exhibits activity in patients whose tumor harbor ALK
fusion proteins [23]. However, there are few preclinical data for this
compound in NSCLC models and how it compares with other ALK
SMIs. We therefore compared TAE684 with PF2341066 in the two
NSCLC models that contain EML4-ALK fusions. As shown in
Figure 4A, although PF2341066 is able to reduce survival of H2228
and H3122 cells, it is much less potent compared with TAE684. The
IC50 for PF2341066 is 871 and 1551 nM for H2228 and H3122, re-
spectively, comparedwith 16 (H2228) and 44 nM (H3122) for TAE684.
In xenograft models, TAE684 at 10 mg/kg resulted in complete re-
gression of H2228 tumors within a week, whereas PF2341066 at the
same dose has no effect on the tumor growth (Figure 4B, upper panel ).
The amount of 100 mg/kg of PF2341066 was needed for tumor re-
gression in this model (n = 10, P = 2 × 10−18). However, even at this
dose level, it took longer to achieve complete regression compared with
TAE684 (Figure 4B, upper panel; P = 8.3 × 10−5, TAE684 10 mg/kg
vs PF2341066 100 mg/kg). In the H3122 model, treatment with
TAE684 at either 10 or 50 mg/kg resulted in tumor regression, whereas
treatment with PF2341066 had a marginal effect on tumor growth at
the same dose levels (Figure 4B, lower panel ). Even at 100 mg/kg,
Figure 4. PF2341066 is not as potent as TAE684 in the inhibition of EML4-ALK fusions in NSCLC. (A) Effect on H2228 and H3122 in vitro
growth. Cells were treated with indicated concentrations of TAE684 (upper panel) or PF2341066 (lower panel), and cell viability was mea-
sured by CellTiterGlo 72 hours after treatment. (B) Effect on H2228 and H3122 xenograft tumor growth. A total of 5 × 106 cells were im-
planted sc into nudemice.When the average tumor size reached 300mm3,micewere randomized into different treatment groups. TAE684
and PF2341066 were administered per os daily at the indicated doses or vehicles (TAE684: 10% 1-methyl-2-pyrrolidinone/90% PEG30,
PF2341066: water). n= 10 for each treatment group. P values for H2228model are as follows: P= .38 (PF 10mg/kg vs vehicle), P= .0002
(PF 50 vs 10mg/kg), P=2× 10−18 (PF 100 vs 50mg/kg), P=8× 10−5 (TAE 10mg/kg vs PF 100mg/kg). H3122model: P= .3 (PF 10mg/kg
vs vehicle), P= .22 (PF 50mg/kg vs vehicle), P= .005 (PF 100mg/kg vs vehicle), P=10−6 (TAE 10mg/kg vs PF 100mg/kg), P=1.7× 10−11
(TAE 50 vs 10 mg/kg).
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PF2341066 only moderately inhibited tumor growth (Figure 4B, lower
panel; P = .005). No significant body weight loss was observed in all
treatment groups. These results suggest that PF2341066 is not as a
potent inhibitor of EML4-ALK compared with TAE684.
Identification of a Gene Signature of EML4-ALK Inhibition
by TAE684 in H2228 Cells
To investigate further the mechanisms involved in TAE684 inhibi-
tion of EML4-ALK, we performed mRNA profiling of H2228 cells
after TAE684 treatment. Analysis of the microarray data revealed dra-
matic changes in themRNA expression profile ofH2228 xenografts on
treatments with TAE684. The number of differentially expressed genes
(compared with the pretreatment group, FDR < 0.1, fold change > 1.5)
increases during the drug treatment with 1776, 3889, and 6204 genes
at 24, 48, and 72 hours after treatment, respectively (Figure 5A).
Among these genes, 234 are commonly upregulated and 1126 are
commonly downregulated at all three time points. The top bio-
logic processes (the number of genes in each process are listed in
Table W1) represented by these genes include cell cycle, DNA meta-
bolic process, and cell proliferation (Figure 5B), consistent with the
known role of ALK fusion proteins in promoting cell cycle progression.
We then focused our attention on genes known to be involved in cell
cycle or apoptosis pathways. There are 210 genes (the complete list of
the genes and changes in their expression levels after TAE684 treat-
ment are in Table W2) in these pathways that are differentially ex-
pressed at least at one time point compared with the pretreatment
group. Unsupervised hierarchical clustering of the expression profile
of these genes suggested that there are four major groups (Figure 5,
C and D).
Figure 5. Microarray analysis gene expression profile after TAE684 treatment of H2228 xenograft tumors. (A) Venn diagram showing the
overlap between the differentially expressed genes at three time points. (B) Top biologic processes represented by the differentially ex-
pressed genes. P values were from hypergeometric tests. (C) Hierarchical clustering of the expression profile of the genes involved in cell
cycle and apoptosis pathways revealed fourmajor groups. Each row represents one gene, whose expression valueswere scaled tomeans
of zero and SDs of 1 (z-score transformation), and color-coded according to the color key. (D) Expression profiles of the fourmajor clusters.
Each line in the plots represents one gene. The normalized expression value of a gene at each time point is represented by the mean of
z-scores from the five replicates. (E) Expression of representative genes by quantitative polymerase chain reaction. Quantitative polymerase
chain reaction was performed on several selected genes using RNA samples from untreated or 24 hours (bim) or 72 hours (cyclin B1, CDK1,
and TOP2A) after TAE684 treatment. Relative expression levels are shown.
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Genes that are downregulated after TAE684 treatment are in clusters 1
and 2 (Figure 5D). Cluster 1 contains 168 genes that were downregulated
over time, and cluster 2 has 14 genes that were rapidly downregulated
24 hours after dosing and then leveled off. These two clusters include
ALK downstream signaling molecules AKT1, MEK, and ERK, as well
as MAP kinases involved in stress response and apoptosis (JNK2 and
MEKK7). The genes that exhibit strongest inhibition by TAE684 are
those involved in cell cycle progression. TAE684 treatment resulted in
more than a 10-fold decrease in mRNA levels of several cyclins and
cyclin-dependent kinases. TAE684 also strongly downregulated
the expression of topoisomerase IIα (TOP2A, >50-fold) and pitui-
tary tumor transforming gene 1 (PTTG1, 3-fold), two proteins in-
volved in chromosome condensation [27] and chromatid separation
[28,29], respectively. Genes that are upregulated by TAE684 treat-
ment are in clusters 3 (consistently upregulated over time) and
4 (transiently upregulated), representing a total of 28 genes. Bim,
a known apoptosis enhancer protein, and p27/CDKN1B, a tumor
suppressor protein that inhibits cell cycle progression are among
the upregulated genes after TAE684 treatment. We confirmed the
microarray results by performing quantitative polymerase chain re-
action for several representative genes. Figure 5E shows that cyclin
B1, TOP2A, and CDK1 mRNA levels decrease with TAE684 treat-
ment, whereas the expression level of Bim increases, consistent with
the microarray data.
To identify potential PD biomarkers for ALK inhibitor treatment,
we analyzed the 193 genes that are consistently upregulated or down-
regulated and are related to cell cycle and apoptosis for their known
presence in human blood according to the Ingenuity Pathways Analy-
sis tool. Twenty-seven genes that are downregulated (2- to 53-fold) on
TAE684 treatment and are detectable in whole blood or plasma
according to published literatures [30–34] are listed in Table 1. The
expression of these genes could potentially be used to monitor PD
properties of ALK SMIs.
Discussion
In this study, we have assessed the effect of a selective and potent ALK
SMI TAE684 [9,20] on two NSCLC cell lines that contain EML4-
ALK fusion proteins [13,14,20] in vitro and in vivo. Previous studies
have shown that TAE684 exhibits more than 100-fold selectivity over
insulin receptor in cell-based assays [9], and that screening of more
than 600 cancer cell lines showed that only a few cancer cell lines that
contain either ALK fusions or amplification/mutations are sensitive to
TAE684 [20]. Our results show that TAE684 inhibits proliferation
and induces cell cycle arrest, apoptosis, and tumor regression of
NSCLC cell lines containing EML4-ALK fusions, confirming a pivotal
role of EML4-ALK in NSCLC.
H2228, harboring EML4-ALK variant 3 [13], is slightly more sen-
sitive to TAE684 inhibition than H3122 that expresses EML4-ALK
variant 1 [14,20]. The in vitro IC50 on cell viability is 15 and
46 nM, and the dose required for tumor regression is 5 and 30 mg/kg
for H2228 and H3122, respectively. Our results are consistent with
previously published results by McDermott et al. [20], in that both
H2228 and H31222 are extremely sensitive to TAE684. The results
published by Koivunen et al. [14] showed that, whereas H3122 is sen-
sitive to TAE684 inhibition, H2228 is not. It is well known that the
same cell line, such as H2228, may evolve into distinct populations
owing to different cell culture conditions and/or techniques, thus ac-
counting for the differential sensitivity to TAE684.
Furthermore, TAE684 rapidly induces cell cycle arrest in H2228
(Figure 1), but it has no effect on cell cycle progression in H3122
Figure 5. (continued).
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(Figure 3C ). Nevertheless, TAE684 has a greater impact on inducing
apoptosis in H3122, with more than 50% cells undergoing apoptosis
48 hours after treatment, compared with 25% in H2228. The slightly
higher concentration required to achieve EC50 (50% efficacy; 50 nM)
in apoptosis assays compared with the IC50 (15 nM) to measure the
metabolic activity in H2228 cell could be explained by the fact that
TAE684 affects both cell cycle progression and apoptosis.
Consistent with these results, TAE684 inhibits different EML4-
ALK downstream signaling molecules in the two cell lines. Whereas
TAE684 inhibits phosphorylation of ERK, STAT3, as well as Akt in
H2228, it affects only STAT3 and Akt but not ERK in H3122. These
results suggest that ALK SMI may have different modes of action on
various EML4-ALK fusion proteins.
PF2341066, an SMI originally developed for c-Met [21] but also
inhibits ALK kinase activity [22], has been reported to exhibit clinical
activity in cancer patients whose tumors harbor ALK fusion proteins
[23]. However, there are few published data on the activity of this com-
pound in NSCLC models containing EML4-ALK fusions. We there-
fore performed side-by-side comparison of TAE684 and PF2341066
in these models. Our results showed that both H2228 and H3122 are
partially resistant to PF2341066 in the in vitro cell viability assay, with
IC50 of 871 and 1553 nM, respectively, compared with IC50 of 15 and
46 nM for TAE684. In vivo, at least 100 mg/kg of PF2341066 is re-
quired to induce tumor regression in the H2228 model, whereas
TAE684 at 10 mg/kg is more efficacious in the same model. In
the H3122 model, PF2341066 only had a cytostatic effect even at
100 mg/kg, whereas TAE684 at 30 mg/kg induced tumor regression.
These results suggest that PF2341066 is not as potent as TAE684 in
inhibiting EML4-ALK. So far, PF2341066 was reported to achieve
mostly partial responses or stable diseases but not complete response
in clinical trials [23]. It is conceivable that a more potent and selective
ALK SMI could achieve better responses in patients whose cancers har-
bor ALK fusion proteins.
To begin to understand the mechanisms involved in the inhibition
of EML4-ALK by SMI, we conducted a pharmacodynamic study com-
bined with gene profiling in a H2228 xenograft model treated with
TAE684. We identified several biologic processes in which the gene
expression is modulated by TAE684 treatment. On the top of the list
are genes involved in cell cycle. Among the genes that are rapidly and
persistently downregulated by TAE684 (cluster 1, Figure 5C ) are
CDC2, CDC7, and CDK4, involved in promoting the G1- to S-phase
transition, and the prereplication complex machinery such as MCMs
(minichromosome maintenance proteins) whose expression peaks at
the G1-S boundary [35]. This change in gene expression profile is con-
sistent with the observation that treatment ofH2228 cells with TAE684
induces G1 arrest. In addition to theG1-S phase of the cell cycle, TAE684
modulates the expression of genes involved in chromosome condensation
(TOP2A), chromatid separation (PTTG), and spindle checkpoint func-
tions (BUBs, budding uninhibited by benzimidazole) [36], suggesting
that TAE684 affects multiple aspects of the cell cycle. TAE684 seems to
promote apoptosis by upregulating the expression of proapoptotic pro-
teins such as Bim and by downregulating genes in Akt/JNK signaling
pathways including Akt1, IRAK, and MAK9.
We also performed gene profiling in H3122 xenograft tumors (data
not shown). The gene signature inH3122 cell on TAE684 treatment is
overlapping but also different from that of H2228. For example, cell
cycle is not a top biologic process in H3122, but apoptosis is. This is
consistent with our results that TAE684 reduces cell viability in
H3122 by inducing apoptosis with no effect on cell cycle progression.
Among the 210 genes in Figure 5C , many can be detected in blood
[30–34]. These include several cyclins (A2, B1, B2, D3, E1, and E2),
CDC2, CDK2, as well as ALK downstream signaling molecules
(Table 1). The changes in mRNA levels for most of these genes on
TAE684 treatment are dramatic (e.g., 7-fold for cyclin B2 and 53-fold
for TOP2A). TOP2A is frequently amplified in cancers including
breast [36], colon [37], as well as prostate [38] and is a predictive marker
Table 1. Potential PD Biomarkers for ALK SMI Treatment in NSCLC.
Symbol Entrez Gene Name Family Fold Change FDR Adjusted P value
AKT1 v-akt murine thymoma viral oncogene homolog 1 Kinase −3.23 2.48E−10
ATF1 Activating transcription factor 1 Transcription regulator −9.9 1.23E−10
CCNA2 Cyclin A2 Other −41.76 1.8E−13
CCNB1 Cyclin B1 Other −181.97 1.74E−17
CCNB2 Cyclin B2 Other −70.13 1.49E−17
CCNE2 Cyclin E2 Other −48.24 2.76E−16
CDC2 Cell division cycle 2, G1 to S and G2 to M Kinase −32.91 1.49E−17
CDK2 Cyclin-dependent kinase 2 Kinase −4.15 4.53E−12
CHEK1 CHK1 checkpoint homolog (Schizosaccharomyces pombe) Kinase −17.77 2.85E−11
EGFR Epidermal growth factor receptor Kinase −5.6 1.66E−10
H2AFX H2A histone family, member X Other −7.56 3.6E−15
HMGB2 High-mobility group box 2 Transcription regulator −8.3 2.88E−14
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog Enzyme −3.16 5.04E−09
IGFBP3 Insulin-like growth factor binding protein 3 Other −5.71 .00000303
IL8 Interleukin 8 Cytokine −8.4 1.97E−13
IL1R1 Interleukin 1 receptor, type I Transmembrane receptor −5.2 1.16E−11
IL1RAP Interleukin 1 receptor accessory protein Transmembrane receptor −18.67 .000848
IRS1 Insulin receptor substrate 1 Other −6.84 1.84E−11
KITLG KIT ligand Growth factor −4.77 1.03E−11
LMNB1 Lamin B1 Other −21.41 3.38E−15
MAP2K1 Mitogen-activated protein kinase kinase 1 Kinase −3.95 1.61E−11
MAP2K2 Mitogen-activated protein kinase kinase 2 Kinase −3.15 4.98E−08
MYC v-myc myelocytomatosis viral oncogene homolog Transcription regulator −5.59 5.3E−11
PCNA Proliferating cell nuclear antigen Other −5.98 4E−13
PLK1 Polo-like kinase 1 (Drosophila) Kinase −20.76 3.1E−14
SHC1 SHC (Src homolog 2 domain containing) transforming protein 1 Other −4.15 5.17E−12
TOP2A Topoisomerase (DNA) II alpha 170 kDa Enzyme −156.1 1.74E−20
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to cytotoxic drugs such as anthracycline [39]. Cyclin B2 is one of the key
genes required for progression through mitosis and is frequently over-
expressed in cancer. The expression of cyclin B2 is used as a diagnostic
marker for lung cancer [40], a prognostic marker for colorectal cancer
[41], and a PD biomarker for the cyclin-dependent kinase inhibitor se-
liciclib [42]. These genes can therefore be potential PD biomarkers for
monitoring ALK SMI in the treatment of NSCLC.
In conclusion, we have demonstrated that EML4-ALK fusion is an
oncogenic driver in two NSCLC models that harbor this genetic alter-
ation. The primary human NSCLC tumors are more heterogeneous
compared with cell line models and thus may have less dramatic re-
sponses to ALK SMI. PF2341066, a moderately potent inhibitor of
EML4-ALK as demonstrated here, exhibited clinical activity in multi-
ple patients harboring ALK fusion proteins in their tumors [23], con-
firming the pivotal role of ALK fusions in oncogenesis. Therefore, a
more potent and selective ALK SMI should be able to achieve superior
clinical efficacy akin to the effect of Gleevec on BCR-Abl in CML
and GIST.
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Figure W1. Sensitivity of NSCLC cell lines to TAE684. (A) Expression of EML4-ALK in NSCLC cell lines. Upper panel: mRNA expression;
lower panel: protein expression. (B) TAE684 selectivity reduces the viability of NSCLC H2228 that harbors EML4-ALK fusion. Cells were
cultured in medium containing 10% FBS and treated with indicated concentrations of TAE684 for 72 hours. Cell viability was measured
using CellTiter Glo reagent.
Table W1. Cellular Processes and Number of Genes That Are Modulated by TAE684 Treatment in H2228 Xenograft.
GO ID GO Term P No. Genes
GO:0007049 cell cycle 9.73e - 22 151
GO:0006259 DNA metabolic process 1.92e - 15 98
GO:0016043 cellular component organization 2.43e - 12 265
GO:0008283 cell proliferation 8.97e - 12 134
GO:0006996 organelle organization 8.76e - 11 165
GO:0007005 mitochondrion organization 3.93e - 07 26
GO:0006950 response to stress 0.00000264 166
GO:0008219 cell death 0.0000207 117
GO:0016265 death 0.0000249 117
GO:0044238 primary metabolic process 0.0000286 647
GO:0008152 metabolic process 0.0000511 706
GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.000213 359
GO:0007010 cytoskeleton organization 0.00107 52
GO:0006519 cellular amino acid and derivative metabolic process 0.00498 42
GO:0009605 response to external stimulus 0.00539 81
GO:0005975 carbohydrate metabolic process 0.0147 57
GO:0006629 lipid metabolic process 0.018 81
GO:0006091 generation of precursor metabolites and energy 0.0232 36
GO:0009058 biosynthetic process 0.0452 359
GO:0009628 response to abiotic stimulus 0.0693 28
